Acrivon’s Endometrial Cancer Drug ACR-368 Gains Traction with KOL Panel at ESGO Congress
Event summary
- Acrivon Therapeutics will host a KOL panel on February 27, 2026, to discuss interim data from its Phase 2b ACR-368 trial in endometrial cancer.
- The panel includes renowned gynecological oncology experts from the US and EU, such as Panos Konstantinopoulos from Dana-Farber Cancer Institute.
- ACR-368 has received Fast Track and Breakthrough Device designations from the FDA for endometrial cancer treatment.
- The panel follows a late-breaking oral presentation of ACR-368 clinical data at the 2026 ESGO Congress.
The big picture
Acrivon’s focus on precision medicine through its Generative Phosphoproteomics AP3 platform positions it to develop targeted therapies for high-unmet-need cancers like endometrial cancer. The KOL panel and ESGO presentation highlight the growing validation of ACR-368, which could set the stage for broader clinical and commercial adoption. The FDA designations underscore the strategic importance of the trial data, which may influence future investment and partnership opportunities.
What we're watching
- Clinical Efficacy
- How the maturing data from the ACR-368 trial will impact its registrational path and potential approval.
- Regulatory Momentum
- Whether the FDA’s Fast Track and Breakthrough Device designations will accelerate ACR-368’s development timeline.
- Market Differentiation
- The pace at which Acrivon can establish ACR-368 as a differentiated therapy in the competitive endometrial cancer space.
Related topics